The Challenge

More than 138,000 U.S. patients and 1.4 million patients worldwide struggle with malignant brain tumors. By the end of the year, another 256,000 will be diagnosed. For the most common tumor – glioblastoma – nine out of ten will lose control of their disease within five years.

The Charge

There is a better way forward by focusing our efforts on the singular goal of finding unique drug trials tailored to individual patients. With this goal in mind, the Ivy Brain Tumor Center is leading a national campaign to quickly identify new methods of treatment. How? Through Phase 0 clinical trials.
Once enrolled in the Phase 0 clinical trial, Patient X is given a single dose of an experimental drug combination developed specifically for their tumor before a planned surgery.

During Patient X’s scheduled surgery, the Ivy Brain Tumor Center team collects and tests tumor tissue to determine the drug’s impact.

With the tissue collected from Patient X, the Ivy Brain Tumor Center’s team of doctors test and analyze whether the drug reached the tumor, how the drug acted after injection and how the tumor responded to the drug.

Depending on the accessibility of the results, Patient X may need extra tests such as biopsies, scans, and blood samples as part of the study process.

In seven days, if the drug combination appears to have reached the tumor or impacted it successfully, the patient will move forward with receiving a full-dose of the drug – skipping immediately to a Phase 2 clinical trial.

If the drug combination has no effect on the tumor, the patient will be diverted to another clinical trial without losing time or receiving an ineffective drug.